New weekly shot could help control blood sugar in type 2 diabetes

NCT ID NCT07156500

Not yet recruiting Disease control Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This Phase 3 study tests a new drug called HS-20094, given as a weekly injection, in 204 adults with type 2 diabetes that is not well controlled by diet and exercise alone. Participants will receive either the drug or a placebo for up to 52 weeks. The main goal is to see if the drug lowers blood sugar levels (HbA1c) more than placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HS-20094 injection
What this could lead to: If successful, this could provide a new weekly injection to help people with type 2 diabetes better control their blood sugar and possibly lose weight.
What could go wrong: This is an early Phase 3 trial with only 204 participants, so results may not apply to everyone. The drug may not work better than placebo or could have side effects not yet known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES

Contacts and locations

Show contact details

Locations

Beijing Hospital

Beijing, Beijing Municipality, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.